FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589612989> ?p ?o ?g. }

• W2589612989 endingPage "624" @default.
• W2589612989 startingPage "624" @default.
• W2589612989 abstract "624 Background: Patients with HER2-positive (HER2+) ESBC generally receive trastuzumab (H) containing chemotherapy adjuvant regimens, either anthracycline (A) containing (AC-TH or similar) or non-anthracycline containing (TCH or similar). This study evaluated patient characteristics and treatment patterns of patients with HER2 + ESBC who receive a H-containing regimen in a community setting. Methods: We conducted a retrospective study utilizing US Oncology’s iKnowMed EMR system. Female patients with HER2+ ESBC initiating adjuvant ACTH, TCH, ACTH-like or TCH-like regimens from 1-1-2006 to 6-30-2009 were identified. Patients in clinical trials or receiving concurrent treatment for other primary cancers were excluded. Patients were followed through 9-30-2010 to observe the duration of adjuvant treatment and reason for regimen discontinuation. Pearson chi square test for frequencies and logistic regression analyses were used for between group comparisons and to determine variables that predicted receipt of anthracycline based regimens. Results: We identified 1,029 patients with HER2+ ESBC who initiated an adjuvant regimen containing H between 1-1-2006 to 6-30-2009. Of these, 225 patients initiated ACTH, 158 patients initiated an ACTH-like regimen, 470 initiated TCH and 176 patients initiated a TCH-like regimen. Younger patients (OR: 2.33) and patients with higher stage at diagnosis (OR: 2.37) are significantly more likely (p<0.001) to receive an A based regimen. The treatment duration in the H product label is 448 days for ACTH and 365 days for TCH. The median (mean) treatment duration observed in this study was 392 (371) days for ACTH, 364 (305.1) days for ACTH like, 364 (299) days for TCH and 371 (329.7) for TCH like patients. The major reason for discontinuation was completion of treatment; toxicity was reported as a reason for discontinuation in 7.2% for ACTH and 1% for TCH. Conclusions: Younger patients with more aggressive disease were more likely to receive ACTH or ACTH like regimens of chemotherapy. The median duration of treatment was closer to the duration in product label for the TCH group versus ACTH with more patients on ACTH stopping treatment due to toxicity." @default.
• W2589612989 created "2017-03-03" @default.
• W2589612989 creator A5032187510 @default.
• W2589612989 creator A5043764554 @default.
• W2589612989 creator A5050234515 @default.
• W2589612989 creator A5072015843 @default.
• W2589612989 creator A5088119887 @default.
• W2589612989 date "2011-05-20" @default.
• W2589612989 modified "2023-10-18" @default.
• W2589612989 title "Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen." @default.
• W2589612989 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.624" @default.
• W2589612989 hasPublicationYear "2011" @default.
• W2589612989 type Work @default.
• W2589612989 sameAs 2589612989 @default.
• W2589612989 citedByCount "0" @default.
• W2589612989 crossrefType "journal-article" @default.
• W2589612989 hasAuthorship W2589612989A5032187510 @default.
• W2589612989 hasAuthorship W2589612989A5043764554 @default.
• W2589612989 hasAuthorship W2589612989A5050234515 @default.
• W2589612989 hasAuthorship W2589612989A5072015843 @default.
• W2589612989 hasAuthorship W2589612989A5088119887 @default.
• W2589612989 hasConcept C121608353 @default.
• W2589612989 hasConcept C126322002 @default.
• W2589612989 hasConcept C141071460 @default.
• W2589612989 hasConcept C143998085 @default.
• W2589612989 hasConcept C2776802502 @default.
• W2589612989 hasConcept C2777863537 @default.
• W2589612989 hasConcept C2778336483 @default.
• W2589612989 hasConcept C2778715236 @default.
• W2589612989 hasConcept C2779786085 @default.
• W2589612989 hasConcept C2781413609 @default.
• W2589612989 hasConcept C530470458 @default.
• W2589612989 hasConcept C71924100 @default.
• W2589612989 hasConceptScore W2589612989C121608353 @default.
• W2589612989 hasConceptScore W2589612989C126322002 @default.
• W2589612989 hasConceptScore W2589612989C141071460 @default.
• W2589612989 hasConceptScore W2589612989C143998085 @default.
• W2589612989 hasConceptScore W2589612989C2776802502 @default.
• W2589612989 hasConceptScore W2589612989C2777863537 @default.
• W2589612989 hasConceptScore W2589612989C2778336483 @default.
• W2589612989 hasConceptScore W2589612989C2778715236 @default.
• W2589612989 hasConceptScore W2589612989C2779786085 @default.
• W2589612989 hasConceptScore W2589612989C2781413609 @default.
• W2589612989 hasConceptScore W2589612989C530470458 @default.
• W2589612989 hasConceptScore W2589612989C71924100 @default.
• W2589612989 hasIssue "15_suppl" @default.
• W2589612989 hasLocation W25896129891 @default.
• W2589612989 hasOpenAccess W2589612989 @default.
• W2589612989 hasPrimaryLocation W25896129891 @default.
• W2589612989 hasRelatedWork W141138677 @default.
• W2589612989 hasRelatedWork W1834621555 @default.
• W2589612989 hasRelatedWork W1986355551 @default.
• W2589612989 hasRelatedWork W2013223170 @default.
• W2589612989 hasRelatedWork W2401765432 @default.
• W2589612989 hasRelatedWork W2801666719 @default.
• W2589612989 hasRelatedWork W2886221980 @default.
• W2589612989 hasRelatedWork W2955988240 @default.
• W2589612989 hasRelatedWork W2969515167 @default.
• W2589612989 hasRelatedWork W4361256061 @default.
• W2589612989 hasVolume "29" @default.
• W2589612989 isParatext "false" @default.
• W2589612989 isRetracted "false" @default.
• W2589612989 magId "2589612989" @default.
• W2589612989 workType "article" @default.